pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL
Autolus
Autolus GmbH
Autolus clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Munich, Bayern 81377, DE
- Employees
- 117
- Programs
- 16
- Drugs
- 17
- Patents
- 49
Autolus projects
4 ClinicalTrials.gov programs sponsored by Autolus.
Autolus has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AUTO1-MS1
Autolus GmbH
Refractory Progressive Multiple Sclerosis
1 trial -
AUTO1-SL1
Autolus GmbH
Severe, Refractory Systemic Lupus Erythematosus
1 trial -
Obecabtagene autoleucel (obe-cel)
Autolus GmbH
Progressive Multiple Sclerosis
1 trial -
Obecabtagene autoleucel (obe-cel)
Autolus GmbH
Systemic Lupus Erythematosus
1 trial
Frequently asked questions
How many clinical projects does Autolus have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.